Novocure LUNAR phase 3 NSCLC trial met primary endpoint; results at ASCO 2023

NovoCure Ltd

LUNAR trial showed statistically significant improvement in overall survival with TTFields plus standard therapies in metastatic NSCLC.
Full results to be presented as a late-breaking abstract at ASCO 2023 on June 6, 2023, at 11:09 a.m. CDT.
Novocure will host an investor event on June 6 at 2 p.m. CDT to discuss the data.
First phase 3 trial evaluating TTFields outside the brain and with immunotherapy.
Ten abstracts on TTFields therapy, including LUNAR, will be presented at ASCO 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.